Article
09 Jan 2026
FDA Launches The TEMPO Pilot For Digital Health Devices To Improve Patient Access To Technologies
AUTHORS CONTENT
Article
23 Dec 2025
FDA Proposes Rule To Reclassify Oncology Therapeutic Nucleic Acid-Based Test Systems As Class II Devices
Article
20 Aug 2025
Commerce Department Singles Out Harvard For Bayh-Dole March-In Rights Enforcement
Article
26 May 2025
Montana Set To Become A "Wild West" Hub For Experimental Medical Treatments And Therapies
Article
19 Feb 2025
FDA AI Guidance - A New Era For Biotech, Diagnostics And Regulatory Compliance
Article
18 Feb 2025
FDA Releases Draft AI Guidance – A New Era For Biotech, Diagnostics And Regulatory Compliance
Article
20 Aug 2024
Patent Primogeniture: First-Filed, First-Issued And Later-Expiring Patent In A Family Immune From A Finding Of Obviousness-Type Double Patenting
Article
24 May 2024
FDA Finalizes New Rule For Lab-Developed Tests
Article
22 May 2024
FDA's New Rule Regulates Lab-Developed Tests Under FD&C Act
Article
01 May 2024
USPTO Proposes Significant Fee Increases Impacting Patent Prosecution Practices
Article
18 Dec 2023
White House Announces Framework For Use Of March-In Rights Under The Bayh-Dole Act To Lower Drug Prices
Article
09 Aug 2022
Coordinating IP And Regulatory Filings Can Minimize The Risk Of Inequitable Conduct Before The PTO
Article
11 Jul 2022
Silence Is Not Necessarily Golden For Negative Patent Claim Limitations
Article
30 Mar 2022
Russian Sanctions Could Impact IP Holdings In Russia And Eurasia
Article
11 May 2020
HHS Clarifies Broad Scope Of Immunity Protection Under The PREP Act
Article
08 May 2020
U.S. Food & Drug Administration Takes Steps To Allow Availability Of PPE
Article
21 Apr 2020
Immunity Protections Expanded Under CARES Act For Covered Countermeasures And Healthcare Volunteers
Article
21 Apr 2020
CARES Act Package Ushers In Changes To OTC Drug Review Process
Article
13 Dec 2019
Spate Of FDA And FTC Warning Letters Sets Stage For Wave Of False Advertising Consumer Class Action Lawsuits
Article
30 Jul 2019
FTC Issues Report On Its Authority Under Section 5 Of The FTC Act To Challenge Pharmaceutical Drug Price Increases